Department of Obstetrics and Gynecology, Penn State University Hershey Medical Center, Hershey, Pennsylvania; the Bixby Center for Global Reproductive Health, University of California, San Francisco, San Francisco, California; the Department of Obstetrics and Gynecology, University of Texas Rio Grande Valley, Edinburg, Texas; and the Department of Obstetrics and Gynecology, University of Tennessee Medical Center, Knoxville, Tennessee.
Corresponding author: Sarah Horvath, MD, MS, Department of Obstetrics and Gynecology, Penn State University Hershey Medical Center, Hershey, PA; email: [email protected].
Financial Disclosure Sarah Horvath disclosed that she receives payment as a Nexplanon trainer for Merck/Organon. Tony Ogburn disclosed receiving funds from ACOG, ABOG, and SASGOG. They disclosed the following: financial relationships: ACOG—Member of Indian Affairs Committee, Healthcare for Underserved Women Committee, CREOG Council (term expired 2020); GOAG (term expired 2019); and consultant to Ethiopia Project (2016–2018). Received travel support and consultant fees for development of educational materials from: ABOG as an oral board examiner. Received travel reimbursement from: APGO—Board member (2018–2020); SASGOG—President, Board Member; Cancer Prevention and Research Institute of Texas (CPRIT)—research support on cervical cancer prevention study. Nikki Zite disclosed receiving an Organon Investigator-Initiated Research Grant. The other authors did not report any potential conflicts of interest.
Presented as a poster at the American College of Obstetricians and Gynecologists' Annual Clinical and Scientific Meeting, held virtually, April 30–May 2, 2021.
Each author has confirmed compliance with the journal's requirements for authorship.
Peer reviews and author correspondence are available at https://links.lww.com/AOG/C503.
